The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill
COVID-19: Single Centered Experience Case Page 1 319 Acta Med Indones - Indones J Intern …

Background Severe and critical COVID-19 disease is characterized by hyperinflammation
involving pro-inflammatory cytokines, particularly IL-6. Tocilizumab is a monoclonal antibody …

Elevated concentrations of interleukin-6 have been demonstrated to be an important key
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …

Severe COVID-19 pneumonia is a principal cause of death due to cascade of hyper
inflammatory condition that leading to lung damage. Therefore, an effective therapy to …

Abstract Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia
and acute respiratory distress syndrome which may lead to death. Several treatments have …

Introduction COVID-19 caused by severe acute respiratory syndromecoronavirus 2 (SARS-
CoV2) has resulted in many deaths worldwide. The pathophysiology of COVID-19 involves …

Background The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms
to severe complications, including acute respiratory distress syndrome. In this syndrome …

Background COVID-19 is a new disease that appeared in December 2019. Millions of
people have been infected and died from this infection. Until today, the pathophysiology and …

Background COVID-19 is characterized by fast deterioration in the mechanism of cytokine
storm. Therefore, treatment with immunomodulating agents should be initiated as soon as …

Abstract This Mini Review of the literature aimed to assess the role of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Based on the available scientific …